Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens [published erratum appears in J Exp Med 1993 Feb 1;177(2):following 576]

doi:10.1084/jem.176.5.1483

This Article

	Full Text (PDF, 730K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Rawlings, D. J.
	Articles by Kaslow, D. C.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Rawlings, D. J.
	Articles by Kaslow, D. C.


Social Bookmarking

	What's this?

ARTICLES

Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens [published erratum appears in J Exp Med 1993 Feb 1;177(2):following 576]

DJ Rawlings and DC Kaslow
Molecular Vaccine Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.

Immune responses in major histocompatibility complex (MHC)-disparate congenic mouse strains immunized with sexual stage malaria parasites or purified recombinant protein were adjuvant dependent. Whereas mice exhibited a limited antibody response to immunization with newly emerged Plasmodium falciparum gametes in Freund's adjuvant, all five congenic mouse strains responded to several transmission-blocking vaccine candidate antigens, when parasites were emulsified in a monophosphoryl lipid A (MPL) and trehalose dimycolate (TDM) adjuvant. The humoral response in those animals immunized with the antigen in a MPL/TDM adjuvant was helper T cell dependent, as evident by boosting of the antibody response after a second immunization. If the immunogen consisted of purified recombinant protein, then the immune response was not MHC class II limited in mice immunized with either complete Freund's adjuvant or TDM/MPL. The potential role of adjuvants in overcoming apparent immune nonresponsiveness and the implications for development of a malaria transmission-blocking vaccine are discussed.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Hui, G., Choe, D., Hashimoto, C. (2008). Biological Activities of Anti-Merozoite Surface Protein-1 Antibodies Induced by Adjuvant-Assisted Immunizations in Mice with Different Immune Gene Knockouts. CVI 15: 1145-1150 [Abstract] [Full Text]
Saxena, A. K., Wu, Y., Garboczi, D. N. (2007). Plasmodium P25 and P28 Surface Proteins: Potential Transmission-Blocking Vaccines. Eukaryot Cell 6: 1260-1265 [Full Text]
Stowers, A. W., Keister, D. B., Muratova, O., Kaslow, D. C. (2000). A Region of Plasmodium falciparum Antigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking Antibodies. Infect. Immun. 68: 5530-5538 [Abstract] [Full Text]
Lobo, C. A., Dhar, R., Kumar, N. (1999). Immunization of Mice with DNA-Based Pfs25 Elicits Potent Malaria Transmission-Blocking Antibodies. Infect. Immun. 67: 1688-1693 [Abstract] [Full Text]
Hui, G. S.�N., Hashimoto, C. N. (1998). Pathways for Potentiation of Immunogenicity during Adjuvant-Assisted Immunizations with Plasmodium falciparum Major Merozoite Surface Protein 1. Infect. Immun. 66: 5329-5336 [Abstract] [Full Text]